Cargando…

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer

PURPOSE: This preliminary study was conducted to evaluate the association between Oncotype DX (ODX) recurrence score and traditional prognostic factors. We also developed a nomogram to predict subgroups with low ODX recurrence scores (less than 25) and to avoid additional chemotherapy treatments for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sae Byul, Kim, Junetae, Sohn, Guiyun, Kim, Jisun, Chung, Il Yong, Kim, Hee Jeong, Ko, Beom Seok, Son, Byung Ho, Ahn, Sei-Hyun, Lee, Jong Won, Jung, Kyung Hae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639212/ https://www.ncbi.nlm.nih.gov/pubmed/30384581 http://dx.doi.org/10.4143/crt.2018.357

Ejemplares similares

Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
por: Kim, Jae-Myung, et al.
Publicado: (2018)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
por: Davey, Matthew G., et al.
Publicado: (2022)

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Lee, Young Joo, et al.
Publicado: (2021)

Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
por: Kim, Jinkyoung, et al.
Publicado: (2019)

Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019)

Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)

Oncotype Dx Results in Multiple Primary Breast Cancers
por: Toole, Michael J., et al.
Publicado: (2014)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2019)

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
por: Song, Ran, et al.
Publicado: (2023)

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
por: Orucevic, Amila, et al.
Publicado: (2017)

Use of Oncotype DX in Women with Node-Positive Breast Cancer
por: Ishibe, Naoko, et al.
Publicado: (2011)

Utilization of Oncotype DX in an Inner City Population: Race or Place?
por: Guth, Amber A., et al.
Publicado: (2013)

P121. Oncotype DX use in N1 disease: A constructive consequence of COVID-19?
por: Whitehead, Ian, et al.
Publicado: (2021)

Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting
por: Malo, Teri L., et al.
Publicado: (2012)

MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023)

A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer
por: Lee, Sae Byul, et al.
Publicado: (2018)

Differential cross sections for $np \to dX$ at 1.0 and 2.0 GeV
por: Sawada, S, et al.
Publicado: (1996)

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
por: Sahebjam, S, et al.
Publicado: (2011)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
por: Zhu, Xiaofu, et al.
Publicado: (2021)

The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
por: Iles, Kathleen, et al.
Publicado: (2022)

The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting
por: Choi, Joseph Do Woong, et al.
Publicado: (2022)

Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
por: Sohn, Guiyun, et al.
Publicado: (2016)

Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2023)

Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer
por: Lee, Lik Hang, et al.
Publicado: (2017)

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study
por: Lee, Sae Byul, et al.
Publicado: (2018)

Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX(® )Colon Cancer Assay
por: Clark-Langone, Kim M, et al.
Publicado: (2010)

Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer
por: Mislick, Kimberly, et al.
Publicado: (2014)

Population-based study of hormone receptor status comparing Oncotype DX with standard immunohistochemistry
por: Baehner, FL, et al.
Publicado: (2009)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer
por: Malam, Yogeshkumar, et al.
Publicado: (2021)

HER2 assessment using fluorescence in situ hybridization compared with Oncotype DX and association with risk of breast cancer death
por: Baehner, FL, et al.
Publicado: (2009)

Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
por: Lin, Hao-Kuen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qtaghms18cm21l40hfg79iv2or